<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21991" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Functional Asplenism</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hijazi</surname>
            <given-names>Laura S.</given-names>
          </name>
          <aff>CMU</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zahra</surname>
            <given-names>Farah</given-names>
          </name>
          <aff>Northwestern Mchenry/RFMUS</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yarrarapu</surname>
            <given-names>Siva Naga S.</given-names>
          </name>
          <aff>Monmouth Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mead</surname>
            <given-names>Therese</given-names>
          </name>
          <aff>Central Michigan University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Laura Hijazi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Farah Zahra declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Siva Naga Yarrarapu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Therese Mead declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>4</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21991.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>The spleen, a vital component of the immune system, plays multiple crucial roles in the body, including immune response modulation and blood filtration, and serving as a key site for the production of antibodies and blood cells, while also acting as a reservoir for platelets. However, conditions like asplenism, whether complete or functional, can compromise these functions, increasing the risk of infections, especially those caused by encapsulated bacteria. "Asplenism" refers to the complete absence of the spleen, which can be due to congenital conditions, surgical removal, or certain diseases. On the other hand, functional asplenism is characterized by the spleen's reduced or impaired function without the organ's complete absence. Functional asplenism can increase the risk of certain infections, particularly those caused by polysaccharide-encapsulated bacteria, such as Streptococcus pneumoniae and other Streptococcal species, Haemophilus influenzae type b, Neisseria meningitidis, Escherichia coli, Salmonella, Klebsiella.</p>
        <p>Participants in this activity explore the multifaceted nature of functional abdominal pain syndrome (FAPS), learning about its clinical presentation, diagnostic criteria, and treatment options. The course covers various approaches to evaluation, including history taking, physical examination, and diagnostic testing, along with the importance of ruling out other organic causes of abdominal pain. Learners gain insights into the management of FAPS, which may include lifestyle modifications, dietary interventions, psychological therapies, and pharmacological treatments. Through interprofessional collaboration, clinicians enhance their competence in addressing the complex needs of patients with FAPS, fostering improved communication and coordination among healthcare team members to provide comprehensive and patient-centered care.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the underlying factors that may lead to functional asplenia, a condition characterized by the reduced or absent function of the spleen.</p></list-item><list-item><p>Screen patients at risk for functional asplenism, including those with underlying conditions or a history of splenectomy.</p></list-item><list-item><p>Review the management options available for functional asplenism and be able to implement them appropriately.</p></list-item><list-item><p>Explain interprofessional team strategies for improving care coordination and communication to diagnose and advance the management of functional asplenism to&#x000a0;improve patient quality of life,&#x000a0;longevity, and outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21991&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21991">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21991.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The spleen is the largest lymphoid organ in the body, playing a crucial role in the immune system and fostering the production and maturation of essential components such as immunoglobulin M, B lymphocytes, and opsonins within its confines. One critical function of the spleen is to protect the body against infections from polysaccharide-encapsulated bacteria, such as&#x000a0;<italic toggle="yes">Streptococcus pneumoniae&#x000a0;</italic>and other Streptococcal species (eg,&#x000a0;<italic toggle="yes">Haemophilus influenzae</italic>&#x000a0;type b,&#x000a0;<italic toggle="yes">Neisseria meningitidis</italic>,&#x000a0;<italic toggle="yes">Escherichia coli</italic>,&#x000a0;<italic toggle="yes">Salmonella</italic>,&#x000a0;<italic toggle="yes">Klebsiella)</italic>.</p>
        <p>Additionally, the spleen acts as the primary reservoir for platelets and serves as a filter for red blood cells, eliminating damaged or malformed cells from circulation. Further, the spleen facilitates extramedullary hematopoiesis, a process crucial for blood cell production.<xref ref-type="bibr" rid="article-21991.r1">[1]</xref><xref ref-type="bibr" rid="article-21991.r2">[2]</xref><xref ref-type="bibr" rid="article-21991.r3">[3]</xref>&#x000a0;Functional asplenism, also known as "functional hyposplenism" or "splenic hypofunction," is a medical condition where the spleen is structurally intact but does not function properly. The term "functional asplenia" was coined by Pearson et al in 1969 while studying patients with sickle cell anemia.<xref ref-type="bibr" rid="article-21991.r4">[4]</xref></p>
      </sec>
      <sec id="article-21991.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Functional asplenism is characterized by the absence of phagocytic activity while maintaining the presence of splenic tissue, and occurs as a result of:</p>
        <list list-type="bullet">
          <list-item>
            <p>Autoimmune disorders such as systemic lupus erythematosus, Hashimoto thyroiditis, antiphospholipid syndrome, rheumatoid arthritis, or autoimmune polyglandular syndrome type 1, also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy&#x000a0;<xref ref-type="bibr" rid="article-21991.r5">[5]</xref><xref ref-type="bibr" rid="article-21991.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Inflammatory conditions such as multiple sclerosis, celiac disease, inflammatory bowel disease, hepatic cirrhosis, sickle cell disease, beta thalassemia, chronic graft-versus-host disease, and nephrotic syndrome&#x000a0;<xref ref-type="bibr" rid="article-21991.r7">[7]</xref><xref ref-type="bibr" rid="article-21991.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Advanced human immunodeficiency virus infection&#x000a0;<xref ref-type="bibr" rid="article-21991.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Hematologic-oncogenic disorders like acute leukemias, non-Hodgkin lymphoma, and advanced breast cancer</p>
          </list-item>
          <list-item>
            <p>Therapies including bone marrow transplantation, high-dose corticosteroids, splenic irradiation, and total parenteral nutrition</p>
          </list-item>
          <list-item>
            <p>Other disorders like amyloidosis, primary biliary cirrhosis, and primary pulmonary hypertension&#x000a0;<xref ref-type="bibr" rid="article-21991.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21991.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The incidence of functional asplenism is contingent upon the prevalence and incidence rates of the precipitating disease.&#x000a0;Below are several epidemiological studies on functional asplenia:</p>
        <list list-type="bullet">
          <list-item>
            <p>In contrast to hypersplenism typically observed in alcoholic liver disease, hyposplenism may also occur in some instances. In a study of 82 patients with alcoholic liver disease, the effects of hyposplenism were monitored over 2 years. Among the patients, 16% died, and 6% had pitted erythrocyte counts similar to splenectomised patients. Abstinence from alcohol for 2 months led to a decrease in pitted erythrocyte count in most patients, while in 2 patients, 1 abstaining and 1 continuing heavy drinking, the count increased.<xref ref-type="bibr" rid="article-21991.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>The prevalence of functional asplenia among individuals with sickle cell disease ranges from 20% to 30% in children and up to 50% in adults. An estimated 1 million individuals in the United States are hyposplenic or asplenic, with approximately 100,000 being attributed to sickle cell disease.<xref ref-type="bibr" rid="article-21991.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>The prevalence of functional asplenia in thalassemia can vary depending on the type and severity of the disease, as well as the patient's age. Results from a 2013 study published in the&#x000a0;<italic toggle="yes">Journal of Pediatric Hematology/Oncology</italic>&#x000a0;revealed that functional asplenia was present in approximately 50% to 75% of patients diagnosed with beta-thalassemia major, the most severe form of the disease.<xref ref-type="bibr" rid="article-21991.r13">[13]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21991.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Functional asplenism is a gradual process that begins with hyposplenism. Researchers theorize that in diseases like sickle cell, the entrapment of red blood cells in the spleen, followed by splenic infarction, leads to hyposplenism. Hyposplenism eventually progresses to functional asplenism through auto-splenectomy. In other hematologic disorders, functional asplenism occurs due to splenic tissue infiltration caused by several mechanisms, including tumor cell infiltration, sarcoidosis, amyloid deposition, or vascular occlusion.<xref ref-type="bibr" rid="article-21991.r8">[8]</xref>&#x000a0;</p>
        <p>Further research exploring and understanding the underlying mechanisms and intricate processes leading to functional asplenism is essential to develop more effective treatments and targeted therapies to improve the overall management of patients affected by these complex hematologic conditions and enhance the quality of life for those experiencing functional asplenism.</p>
      </sec>
      <sec id="article-21991.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathology proves invaluable in diagnosing and managing functional asplenism. This detailed analysis provides crucial insights, aiding healthcare professionals in accurate diagnosis and effective treatment strategies tailored to individual patients. Early recognition and appropriate management of functional asplenism are essential to preventing life-threatening infections.<xref ref-type="bibr" rid="article-21991.r14">[14]</xref></p>
        <p>One of the key features of functional asplenism is the absence or reduction of white pulp in the spleen due to a decrease in the size and number of lymphoid follicles&#x02014;the basic structural units of the white pulp. The lymphoid follicles contain B- and T-lymphocytes, critical immune system components. The white pulp filters the blood and removes foreign particles, such as bacteria and viruses. Without a functional white pulp, individuals with functional asplenism are at increased risk of developing infections, particularly from encapsulated bacteria such as&#x000a0;<italic toggle="yes">S pneumoniae</italic>,&#x000a0;<italic toggle="yes">H influenzae</italic>&#x000a0;type b, and&#x000a0;<italic toggle="yes">N meningitidis</italic>. These infections can be serious and life-threatening and can lead to the overwhelming post-splenectomy infection syndrome.<xref ref-type="bibr" rid="article-21991.r15">[15]</xref>&#x000a0;</p>
        <p>In addition to a decrease in lymphoid follicles, there may be an increase in the red pulp, which is responsible for filtering and storing red blood cells.&#x000a0;Histopathology can provide essential insights into the underlying pathology of functional asplenism. In addition, the characteristic decrease in white pulp and increase in red pulp can help diagnose and manage various conditions associated with functional asplenism, including sickle cell disease, thalassemia, and autoimmune disorders.</p>
      </sec>
      <sec id="article-21991.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>When conducting a history and physical examination on a patient with functional asplenism, the clinician will typically ask about the patient's medical history, including any underlying conditions, such as sickle cell disease or other disorders that can affect spleen function. They may also ask about any previous infections or episodes of fever, which can be more common in patients with functional asplenism.</p>
        <p>During the physical examination, the clinician checks for signs of an enlarged spleen, such as tenderness or a palpable mass in the left upper abdomen. They may also look for signs of infection, such as fever or an elevated white blood cell count. Other physical findings include jaundice (yellowing of the skin and eyes), anemia (low red blood cell count), and a low platelet count.</p>
        <p>Patients with asplenia or hyposplenism who are bitten by an animal, particularly a dog, should seek immediate medical care. These patients are at risk of developing fulminant sepsis from&#x000a0;<italic toggle="yes">Capnocytophaga canimorsus&#x000a0;</italic>infection, which can be fatal.<xref ref-type="bibr" rid="article-21991.r16">[16]</xref>&#x000a0;There is also an increased risk of infection by intra-erythrocyte parasites such as Malaria and&#x000a0;<italic toggle="yes">Babesia.</italic><xref ref-type="bibr" rid="article-21991.r17">[17]</xref>&#x000a0;A rare case of lethal Waterhouse-Friderichsen syndrome due to&#x000a0;<italic toggle="yes">Capnocytophaga canimorsus</italic>&#x000a0;has also been reported in a patient who is asplenic.<xref ref-type="bibr" rid="article-21991.r18">[18]</xref></p>
      </sec>
      <sec id="article-21991.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>A functional hyposplenism diagnosis may be based on hematology, nuclear medicine, ultrasound imaging, or immunological parameters.&#x000a0;The peripheral blood smear is vital for evaluating functional asplenism, as various cells may help identify functional asplenism. Howell-Jolly bodies on a peripheral blood smear indicate abnormal spleen function.<xref ref-type="bibr" rid="article-21991.r19">[19]</xref>&#x000a0;Howell-Jolly bodies are nuclear remnants of old red blood cells (RBCs) typically removed by the spleen (see&#x000a0;<bold>Image.</bold>&#x000a0;Howell-Jolly Body). Although they are typically found on a peripheral blood smear, a flow cytometry-based assay for Howell-Jolly bodies is currently under investigation. Thrombocytosis, lymphocytosis, and monocytosis are additional hematological signs of functional asplenism. Acanthocytes, giant cells, Heinz bodies, and iron granules may also be observed on a peripheral blood smear. Demonstration of many of these abnormalities requires special dyes and microscopy. In addition, the presence and quantitation of "pitted" RBCs have been used to determine the function of remaining splenic tissue.<xref ref-type="bibr" rid="article-21991.r11">[11]</xref>&#x000a0;</p>
        <p>A technetium-99m-labeled radiocolloid scan helps evaluate splenic function by measuring the uptake of injected radio-labeled particles by the splenic endothelium relative to the liver.<xref ref-type="bibr" rid="article-21991.r2">[2]</xref>&#x000a0;This scan provides information regarding the phagocytic function of the spleen. Liver-spleen scintigraphy has the disadvantage of being invasive and time-consuming for patients. Newer methods currently in use include immune response upon vaccination or evaluating the functionality of specific B-cell subsets. Functional asplenia is also associated with small, avascular spleens on Doppler sonography.<xref ref-type="bibr" rid="article-21991.r20">[20]</xref>&#x000a0;Immunological methods such as measuring tuftsin levels are of little clinical significance for evaluating spleen phagocytic function.<xref ref-type="bibr" rid="article-21991.r21">[21]</xref></p>
      </sec>
      <sec id="article-21991.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treating and managing functional asplenism reduces the risk of infections and complications associated with this condition. Some of the recommended strategies include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Vaccinations: Vaccination is an essential aspect of managing functional asplenism. Patients should receive vaccinations against the bacteria that commonly cause infections in people with impaired spleen function, including vaccines against&#x000a0;<italic toggle="yes">S pneumoniae</italic>,&#x000a0;<italic toggle="yes">H influenzae</italic>&#x000a0;type b, and&#x000a0;<italic toggle="yes">N meningitidis</italic>. Patients should also receive annual influenza vaccination to reduce the risk of influenza-related complications. Study results have shown a significant reduction in the percentage of severe infections in patients after immunization with pneumococcal vaccines. The commonly used pneumococcal polysaccharide vaccine is ineffective in those who are asplenic because it requires the presence of immunoglobulin M memory B cells. The pneumococcal conjugate vaccine is more effective in functionally asplenic patients because it employs a T-cell-dependent mechanism and is the preferred vaccine. In addition, vaccines are thought to act better when the spleen is intact. Hence, the vaccine should be given 2 weeks before surgery in patients undergoing splenectomy. Moreover, patients with impaired splenic function should receive 3 doses of messenger ribonucleic acid COVID-19 vaccines, just like other patients who are immunocompromised. This is supported by the notion that a subset of memory B cells in the spleen could exert a protective role against this virus.<xref ref-type="bibr" rid="article-21991.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Antibiotics: Patients with functional asplenia may be prescribed long-term antibiotic prophylaxis to prevent infections. Antibiotics such as penicillin or amoxicillin are typically used for this purpose, but local microorganism resistance should be considered. In addition, antimalarial prophylaxis should be given to patients traveling to malaria-endemic areas.<xref ref-type="bibr" rid="article-21991.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Antibiotic prophylaxis: This is generally reserved for patients who are asplenic or hyposplenic who undergo procedures like endoscopic sinus surgery or bronchoscopy, as encapsulated organisms (such as&#x000a0;<italic toggle="yes">S pneumoniae</italic>&#x000a0;and&#x000a0;<italic toggle="yes">H influenzae</italic>&#x000a0;type b) can colonize these areas, leading to a fatal infection. For adults, 2 grams of amoxicillin is given orally 30 to 60 minutes before the procedure. For children, 3 months of age and older, and weighing less than 40 kg, amoxicillin 50 mg/kg is given an hour before the procedure (maximum dose 2 g). Alternatives include cephalosporins (eg, cephalexin), clindamycin, and macrolides such as azithromycin or erythromycin. Levofloxacin and moxifloxacin can also be used for adults.</p>
          </list-item>
          <list-item>
            <p>Treatment for animal bites in patients who are asplenic should involve thorough wound irrigation and antibiotic therapy that targets Capnocytophaga species. In the event of an animal bite, the first line of treatment consists of a beta-lactam-beta-lactamase inhibitor combination antibiotic, such as piperacillin-tazobactam (4.5 g every 6 hours) or meropenem (2 g every 8 hours) in combination with vancomycin to target Capnocytophaga species. However, meropenem is usually preferred over piperacillin-tazobactam when meningitis is suspected due to its higher penetration into the cerebrospinal fluid.</p>
          </list-item>
          <list-item>
            <p>Education and awareness: Patients with functional asplenism should be educated on the signs and symptoms of infection and when to seek medical attention. Patients should also be encouraged to carry a medical alert card or bracelet that identifies their condition and advises on appropriate management in an emergency.</p>
          </list-item>
          <list-item>
            <p>Regular medical follow-up: Patients with functional asplenism should receive regular medical follow-up to monitor for complications and adjust management as necessary.</p>
          </list-item>
        </list>
        <p>Managing functional asplenia is individualized and may vary depending on the underlying condition causing it. Therefore, consulting a healthcare professional with experience managing functional asplenia is essential.</p>
      </sec>
      <sec id="article-21991.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for functional asplenism includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic lymphocytic leukemia <xref ref-type="bibr" rid="article-21991.r23">[23]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Lymphomas</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Amyloidosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Bone marrow transplant</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Celiac disease</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Glomerulonephritis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Graves disease&#x000a0;<xref ref-type="bibr" rid="article-21991.r24">[24]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hereditary hemoglobinopathies</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Inflammatory bowel disease</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Isolated congenital asplenia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Post splenectomy</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Rheumatoid arthritis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sarcoidosis&#x000a0;<xref ref-type="bibr" rid="article-21991.r25">[25]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Splenic irradiation</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Splenic vein thrombosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tumors, such as lymphoma</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>B-Thalassemia</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21991.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>When recognized and managed adequately with vaccines and proper prophylaxis, people with functional asplenism can lead a long, relatively healthy life despite being immunocompromised. Mortality varies widely in patients who are functionally asplenic depending on the infecting pathogen, underlying comorbidities, and access to vaccines and prophylactic antibiotics, in addition to other factors. Recognition of early sepsis with appropriate treatment can substantially reduce overall mortality.</p>
      </sec>
      <sec id="article-21991.s12" sec-type="Complications">
        <title>Complications</title>
        <p>
<bold>Overwhelming Post-Splenectomy Infection</bold>
</p>
        <p>Overwhelming post-splenectomy infection (OPSI) is a syndrome encountered in patients who have functional asplenia. Bacteremia caused by encapsulated microorganisms characterizes the syndrome, with the most commonly reported pathogen in OPSI being&#x000a0;<italic toggle="yes">Streptococcus pneumoniae</italic>. The syndrome might present without a visible primary source of infection and with a short prodromal phase; clinical presentations include septic shock, disseminated intravascular coagulopathy, and bilateral adrenal hemorrhage. OPSI is a medical emergency, and antibiotics should be administered immediately, along with supportive measures.<xref ref-type="bibr" rid="article-21991.r26">[26]</xref></p>
        <p>Patients who are hyposplenic might already be taking prophylactic antibiotics, and hence, cultures might be negative; however, antibiotic therapy should continue. Empiric parental antibiotic therapy should include vancomycin and either cefotaxime or ceftriaxone. Although the efficacy of intravenous immunoglobulin treatment for asplenic sepsis has not been proven, some experts recommend its administration in this situation. The mortality of OPSI is high, with overall mortality rates of 50% to 70%, and death may result in 24 to 48 hours.</p>
        <p>This syndrome has been observed from 10 years and up to 30 years after diagnosis with hyposplenism. Some studies indicate that the risk of OPSI decreases with the time elapsed since splenectomy, while other studies do not show a significant reduction.&#x000a0;</p>
        <p>
<bold>Thrombocytosis</bold>
</p>
        <p>Functional asplenism is almost always associated with secondary elevation of platelet count because the spleen is the leading site of platelets&#x02019; destruction and provokes reflexive thrombocytosis. However, this is not seen in patients with liver cirrhosis and portal hypertension; these patients present with thrombocytopenia rather than thrombocytosis due to impaired liver function. Thrombocytosis increases the risk of thrombotic events.</p>
        <p>Venous thrombosis in patients with asplenism is associated with platelet counts greater than 600 to 800 k/&#x000b5;L and occurs in approximately 5% of patients. Thrombocytosis can also cause arterial thrombosis, leading to myocardial infarction and cerebrovascular accidents. Some patients take aspirin or even a cytoreductive agent such as hydroxyurea or anagrelide to reduce the risk of thrombotic events.</p>
        <p>
<bold>Acute infectious purpura fulminans</bold>
</p>
        <p>Acute infectious purpura fulminans is a rapidly progressive syndrome of hemorrhagic skin necrosis associated with acute infection due to encapsulated organisms (usually&#x000a0;<italic toggle="yes">Streptococcus pneumoniae&#x000a0;</italic>or group A streptococci) resulting in disseminated intravascular coagulation with a strong predilection for patients with asplenism or functional hyposplenism.<xref ref-type="bibr" rid="article-21991.r27">[27]</xref></p>
      </sec>
      <sec id="article-21991.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be instructed to have an asplenic alert card to inform the healthcare professional that they do not have a functional spleen. They should be current with their vaccinations and have access to prophylactic antibiotics. They must be educated to avoid dog or tick bites and take caution when traveling to malaria-endemic areas.</p>
      </sec>
      <sec id="article-21991.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Knowledge of the spleen's crucial and protective functions shows the importance of recognizing functional asplenism, a condition most commonly seen in patients with autoimmune diseases and various hematological disorders. OPSI, as well as thrombotic events, are serious medical emergencies that require prompt intervention. Prompt recognition of the illness's high-risk nature may limit morbidity.The simple interventions of immunizations and prophylactic antibiotics are expected to reduce the frequency of OPSI and decrease its mortality despite the controversy over antibiotic use in patients.</p>
      </sec>
      <sec id="article-21991.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Patients with functional asplenia require a coordinated care approach involving multiple healthcare professionals, especially hematology and infectious disease teams. Healthcare professionals who care for patients with functional asplenia should have a comprehensive understanding of the immune system and the complications associated with this condition; it is essential to know how to diagnose and manage infections and prevent them through vaccination and other preventive measures. A comprehensive care plan is essential for patients with functional asplenia. The care plan should include follow-up appointments at regular intervals to monitor the patient's condition and a plan for managing potential complications. Healthcare professionals should collaborate with patients and their families to develop a care plan tailored to their needs and preferences. The care plan should also consider the patient's cultural and religious beliefs.Healthcare professionals should take responsibility for their professional development and stay current with the latest research and best practices. In addition, effective communication is essential for ensuring a coordinated approach to care. Collaboration among healthcare professionals ensures that the patient receives comprehensive, coordinated care through sharing information about the patient's condition, treatments, and medications and working together to manage potential complications.</p>
      </sec>
      <sec id="article-21991.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21991&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21991">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/gut-health/functional-asplenism/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=21991">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21991/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21991">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-21991.s17">
        <fig id="article-21991.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Howell-Jolly Bodies. Howell-Jolly bodies appear in peripheral blood smears of patients with absent or impaired spleen function. Contributed by K Humphreys</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="HollyJolly__x1x" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-21991.s18">
        <title>References</title>
        <ref id="article-21991.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balaphas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Harbarth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Amzalag</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Buhler</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Morel</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>[Patient management after splenectomy in 2015: state of the art and recommendations].</article-title>
            <source>Rev Med Suisse</source>
            <year>2015</year>
            <month>Jun</month>
            <day>17</day>
            <volume>11</volume>
            <issue>479</issue>
            <fpage>1345</fpage>
            <page-range>1345-50</page-range>
            <pub-id pub-id-type="pmid">26255496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scheuerman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bar-Sever</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Hoffer</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gilad</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Garty</surname>
                <given-names>BZ</given-names>
              </name>
            </person-group>
            <article-title>Functional hyposplenism is an important and underdiagnosed immunodeficiency condition in children.</article-title>
            <source>Acta Paediatr</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>103</volume>
            <issue>9</issue>
            <fpage>e399</fpage>
            <page-range>e399-403</page-range>
            <pub-id pub-id-type="pmid">24850471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Halbertsma</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Neeleman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Weemaes</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>van Deuren</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The absent and vanishing spleen: congenital asplenia and hyposplenism--two case reports.</article-title>
            <source>Acta Paediatr</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>94</volume>
            <issue>3</issue>
            <fpage>369</fpage>
            <page-range>369-71</page-range>
            <pub-id pub-id-type="pmid">16028659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pearson</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Cornelius</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Functional asplenia in sickle-cell anemia.</article-title>
            <source>N Engl J Med</source>
            <year>1969</year>
            <month>Oct</month>
            <day>23</day>
            <volume>281</volume>
            <issue>17</issue>
            <fpage>923</fpage>
            <page-range>923-6</page-range>
            <pub-id pub-id-type="pmid">5811425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bello</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Garla</surname>
                <given-names>VV</given-names>
              </name>
            </person-group>
            <chapter-title>Polyglandular Autoimmune Syndrome Type I</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30725896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Starzyk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kumorowicz-Kopiec</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kowalczyk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Starzyk</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rybakowa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dziatkowiak</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Natural history of asplenism in APECED--patient report.</article-title>
            <source>J Pediatr Endocrinol Metab</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>443</fpage>
            <page-range>443-9</page-range>
            <pub-id pub-id-type="pmid">11327379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liot&#x000e9;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Angle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gilmore</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Osterland</surname>
                <given-names>CK</given-names>
              </name>
            </person-group>
            <article-title>Asplenism and systemic lupus erythematosus.</article-title>
            <source>Clin Rheumatol</source>
            <year>1995</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>220</fpage>
            <page-range>220-3</page-range>
            <pub-id pub-id-type="pmid">7789066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Comenzo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Malachowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berkman</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Clinical correlation of positive direct antiglobulin tests in patients with sickle cell disease.</article-title>
            <source>Immunohematology</source>
            <year>1992</year>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-6</page-range>
            <pub-id pub-id-type="pmid">15946047</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carrillo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Negredo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Puig</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Molinos-Albert</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez de la Concepci&#x000f3;n</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Curriu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Massanella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Crespo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vi&#x000f1;ets</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mill&#x000e1;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Clotet</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Blanco</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Memory B cell dysregulation in HIV-1-infected individuals.</article-title>
            <source>AIDS</source>
            <year>2018</year>
            <month>Jan</month>
            <day>14</day>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>149</fpage>
            <page-range>149-160</page-range>
            <pub-id pub-id-type="pmid">29112067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suzuki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ino</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mizutani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ohishi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sekine</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Katayama</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>[Multiple myeloma accompanying splenic amyloidosis and overwhelming pneumococcemia].</article-title>
            <source>Rinsho Ketsueki</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>48</volume>
            <issue>11</issue>
            <fpage>1503</fpage>
            <page-range>1503-7</page-range>
            <pub-id pub-id-type="pmid">18080510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muller</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Toghill</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Functional hyposplenism in alcoholic liver disease: a toxic effect of alcohol?</article-title>
            <source>Gut</source>
            <year>1994</year>
            <month>May</month>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>679</fpage>
            <page-range>679-82</page-range>
            <pub-id pub-id-type="pmid">8200565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubin</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Schaffner</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Clinical practice. Care of the asplenic patient.</article-title>
            <source>N Engl J Med</source>
            <year>2014</year>
            <month>Jul</month>
            <day>24</day>
            <volume>371</volume>
            <issue>4</issue>
            <fpage>349</fpage>
            <page-range>349-56</page-range>
            <pub-id pub-id-type="pmid">25054718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Musallam</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Taher</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Cappellini</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Sankaran</surname>
                <given-names>VG</given-names>
              </name>
            </person-group>
            <article-title>Clinical experience with fetal hemoglobin induction therapy in patients with &#x003b2;-thalassemia.</article-title>
            <source>Blood</source>
            <year>2013</year>
            <month>Mar</month>
            <day>21</day>
            <volume>121</volume>
            <issue>12</issue>
            <fpage>2199</fpage>
            <page-range>2199-212; quiz 2372</page-range>
            <pub-id pub-id-type="pmid">23315167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peretz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Livshits</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pretorius</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Makhro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bogdanova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gassmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The protective effect of the spleen in sickle cell patients. A comparative study between patients with asplenia/hyposplenism and hypersplenism.</article-title>
            <source>Front Physiol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>796837</fpage>
            <pub-id pub-id-type="pmid">36105295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kirkineska</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Perifanis</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vasiliadis</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Functional hyposplenism.</article-title>
            <source>Hippokratia</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-11</page-range>
            <pub-id pub-id-type="pmid">25125944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vignon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Combeau</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Violette</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cogn&#x000e9;e</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>M&#x000e9;glio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carr&#x000e8;re</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Aucher</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lellouche</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>[A fatal septic shock due to Capnocytophaga canimorsus and review of literature].</article-title>
            <source>Rev Med Interne</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>39</volume>
            <issue>10</issue>
            <fpage>820</fpage>
            <page-range>820-823</page-range>
            <pub-id pub-id-type="pmid">29706238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Spelman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Woolley</surname>
                <given-names>IJ</given-names>
              </name>
            </person-group>
            <article-title>Post-splenectomy sepsis: preventative strategies, challenges, and solutions.</article-title>
            <source>Infect Drug Resist</source>
            <year>2019</year>
            <volume>12</volume>
            <fpage>2839</fpage>
            <page-range>2839-2851</page-range>
            <pub-id pub-id-type="pmid">31571940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schuler</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Padberg</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Hullermann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>K&#x000fc;mpers</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lepper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schulte</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Uek&#x000f6;tter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schaumburg</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kahl</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Lethal Waterhouse-Friderichsen syndrome caused by Capnocytophaga canimorsus in an asplenic patient.</article-title>
            <source>BMC Infect Dis</source>
            <year>2022</year>
            <month>Aug</month>
            <day>17</day>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>696</fpage>
            <pub-id pub-id-type="pmid">35978295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakagami</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Uchino</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Enomoto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mizuno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hanamura</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nakayama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tani</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takami</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Potential role of Howell-Jolly bodies in identifying functional hyposplenism: a prospective single-institute study.</article-title>
            <source>Int J Hematol</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>112</volume>
            <issue>4</issue>
            <fpage>544</fpage>
            <page-range>544-552</page-range>
            <pub-id pub-id-type="pmid">32572828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joshpe</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rothenberg</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Transient functional asplenism in sickle cell-C disease.</article-title>
            <source>Am J Med</source>
            <year>1973</year>
            <month>Nov</month>
            <volume>55</volume>
            <issue>5</issue>
            <fpage>720</fpage>
            <page-range>720-2</page-range>
            <pub-id pub-id-type="pmid">4749210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>William</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Corazza</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>Hyposplenism: a comprehensive review. Part I: basic concepts and causes.</article-title>
            <source>Hematology</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-13</page-range>
            <pub-id pub-id-type="pmid">17364987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rossi</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Lenti</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Merli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Di Sabatino</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Role of IgM Memory B Cells and Spleen Function in COVID-19.</article-title>
            <source>Front Immunol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>889876</fpage>
            <pub-id pub-id-type="pmid">35844543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r23">
          <label>23</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Montague</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Pathak</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <chapter-title>Chronic Lymphocytic Leukemia With Variant Genetics</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>14</day>
            <pub-id pub-id-type="pmid">36251840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Pokhrel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bhusal</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Graves Disease</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">28846288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r25">
          <label>25</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bokhari</surname>
                <given-names>SRA</given-names>
              </name>
              <name>
                <surname>Zulfiqar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mansur</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Sarcoidosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">28613460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Itagaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Endo</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Overwhelming Post-splenectomy Infection Caused by Escherichia coli 20 Years After Splenectomy: A Case Report.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>15</volume>
            <issue>7</issue>
            <fpage>e42184</fpage>
            <pub-id pub-id-type="pmid">37602031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21991.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ward</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Celebi</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Gmyrek</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Acute infectious purpura fulminans associated with asplenism or hyposplenism.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>493</fpage>
            <page-range>493-6</page-range>
            <pub-id pub-id-type="pmid">12271289</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
